Solid Biosciences INC 10-Q quarterly reports

Solid Biosciences reported a wider net loss in Q1 2026 due to increased R&D investments, but maintained a robust cash position and advanced its gene therapy pipeline.

Solid Biosciences announced positive interim data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, showing promising microdystrophin expression and cardiac benefits.

Solid Biosciences reports increased R&D spend and net losses in Q2 2025, but extends cash runway into H1 2027 following a significant capital raise and positive clinical progress for its gene therapy candidates.

Solid Biosciences reports positive initial data from its Phase 1/2 INSPIRE DUCHENNE trial and anticipates initiating a Phase 1b clinical trial of SGT-212 in the second half of 2025.

Solid Biosciences reported its third quarter 2024 financial results, highlighting progress in its gene therapy programs and a recent asset acquisition.

Solid Biosciences Inc. reported progress in its Phase 1/2 INSPIRE Duchenne trial for SGT-003, alongside advancements in its broader gene therapy pipeline for neuromuscular and cardiac diseases in its Q2 2024 results.

Solid Biosciences reported a net loss of $24.3 million for the first quarter of 2024, while highlighting a significant increase in cash and cash equivalents due to a private placement.